WO1996026958A3 - L'elf-2, ligand du recepteur eph - Google Patents

L'elf-2, ligand du recepteur eph Download PDF

Info

Publication number
WO1996026958A3
WO1996026958A3 PCT/US1996/002673 US9602673W WO9626958A3 WO 1996026958 A3 WO1996026958 A3 WO 1996026958A3 US 9602673 W US9602673 W US 9602673W WO 9626958 A3 WO9626958 A3 WO 9626958A3
Authority
WO
WIPO (PCT)
Prior art keywords
elf
eph receptor
ligand
receptor ligand
dna encoding
Prior art date
Application number
PCT/US1996/002673
Other languages
English (en)
Other versions
WO1996026958A2 (fr
Inventor
John G Flanagan
Andrew D Bergemann
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of WO1996026958A2 publication Critical patent/WO1996026958A2/fr
Publication of WO1996026958A3 publication Critical patent/WO1996026958A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention porte sur un ADN isolé codant pour tout ou partie d'un nouvel élément, l'ELF-2, d'une famille de ligands des tyrosines kinases réceptrices Eph et sur des polypeptides isolés exprimés par ledit ADN. L'invention porte également sur des formes d'ADN codant pour des formes du ligand ELF-2 et les polypeptides correspondants. Le ligand ELF-2 joue un rôle important dans les communications cellulaires lors de la constitution de la morphologie chez l'embryon et peut influer sur le développement neurologique, l'oncogénèse ou la régulation de la croissance.
PCT/US1996/002673 1995-02-27 1996-02-23 L'elf-2, ligand du recepteur eph WO1996026958A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39541595A 1995-02-27 1995-02-27
US08/395,415 1995-02-27

Publications (2)

Publication Number Publication Date
WO1996026958A2 WO1996026958A2 (fr) 1996-09-06
WO1996026958A3 true WO1996026958A3 (fr) 1996-10-10

Family

ID=23562933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/002673 WO1996026958A2 (fr) 1995-02-27 1996-02-23 L'elf-2, ligand du recepteur eph

Country Status (1)

Country Link
WO (1) WO1996026958A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101617108B1 (ko) 2006-01-20 2016-04-29 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1019728A1 (fr) * 1995-10-13 2000-07-19 Mount Sinai Hospital Procede d'activation d'une nouvelle voie de regulation de ligand
DE69635667T2 (de) * 1995-10-25 2006-09-07 Regeneron Pharmaceuticals, Inc. Biologisch aktive liganden der eph familie
CA2259157A1 (fr) 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Recepteurs oligomerises modulant des voies regulees par des ligands transmembranaires pour des recepteurs tyrosine-kinases type elk
CA2308126A1 (fr) 1997-10-02 1999-04-15 Leukosite, Inc. Modulation de l'adhesion cellulaire induite par la lerk-2
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
AU2004201391B2 (en) * 1998-10-27 2007-08-23 The Council Of The Queensland Institute Of Medical Research A method of the treatment
AU773338B2 (en) * 1998-10-27 2004-05-20 Council Of The Queensland Institute Of Medical Research, The A method of treatment
EP1246637A2 (fr) 2000-01-06 2002-10-09 The Hospital for Sick Children Procedes de modulation du systeme immunitaire
WO2002026827A1 (fr) * 2000-09-29 2002-04-04 Novartis Ag Polypeptides extracellulaires de recpteurs eph b et ligands ephrine b, et molecules d'acide nucleiques correspondantes
US7163808B2 (en) 2000-11-20 2007-01-16 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
CA2452578A1 (fr) * 2001-07-03 2003-01-16 The Hospital For Sick Children Immunomodulation induite par les recepteurs ephrin et eph
EP1852441B1 (fr) * 2002-09-24 2012-03-28 The Burnham Institute Agents qui modulent l'activité du récepteur EPH
CA2499580A1 (fr) * 2002-09-24 2004-04-08 The Burnham Institute Nouveaux agents modulant l'activite du recepteur eph
JP4762889B2 (ja) 2003-03-12 2011-08-31 バスジーン セラピューティクス，インコーポレイテッド 血管形成及び腫瘍成長を阻止するための核酸化合物
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
ATE492564T1 (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
EP1799713B1 (fr) 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
KR20070118230A (ko) 2005-01-27 2007-12-14 더 번햄 인스티튜트 Ｅｐｈｂ 수용체-결합 펩티드
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015201A1 (fr) * 1992-01-22 1993-08-05 New England Deaconess Hospital Nouvelles tyrosine kinases de proteines
WO1996002645A2 (fr) * 1994-07-20 1996-02-01 Genentech, Inc. Ligand de htk

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015201A1 (fr) * 1992-01-22 1993-08-05 New England Deaconess Hospital Nouvelles tyrosine kinases de proteines
WO1996002645A2 (fr) * 1994-07-20 1996-02-01 Genentech, Inc. Ligand de htk

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENNETT B D ET AL: "Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily", JOURNAL OF BIOLOGICAL CHEMISTRY, 269 (19). 1994. 14211-14218., XP002010464 *
BENNETT B D ET AL: "Molecular cloning of a ligand for the EPH-related receptor protein tyrosine, kinase-Htk", BLOOD, 84 (10 SUPPL. 1). 1994. 427A. ABSTRACT1693, XP000579052 *
BENNETT B D ET AL: "Molecular cloning of a ligand for the EPH-related receptor protein-tyrosine kinase Htk", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 92 (6). 1995. 1866-1870., XP002010465 *
BERGEMANN A D ET AL: "ELF-2, a New Member of the Eph Ligand Family, Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites", MOLECULAR AND CELLULAR BIOLOGY, 15 (9). 1995. 4921-4929., XP000578783 *
DAVIS, SAMUEL ET AL: "Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity", SCIENCE (WASHINGTON, D. C.) (1994), 266(5186), 816-19 CODEN: SCIEAS;ISSN: 0036-8075, XP002010463 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101617108B1 (ko) 2006-01-20 2016-04-29 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법

Also Published As

Publication number Publication date
WO1996026958A2 (fr) 1996-09-06

Similar Documents

Publication Publication Date Title
WO1996026958A3 (fr) L'elf-2, ligand du recepteur eph
IT8521074A0 (it) Procedimento di preparazione di microlattici invertiti di copolimeri idrosolubili, i microlattici invertiti ottenuti eloro utilizzazione per il miglioramento della produzione degli idrocarburi.
HK1031836A1 (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxa-line-based compounds.
NO881176D0 (no) Korreksjon av funksjonssvekkede veneventiler.
EP1231260A3 (fr) Procédé d'isolement de cellules exprimant des récepteurs FLK-2 sur leur surface
DE3878599T2 (de) Elektromagnetisches kraftstoffeinspritzventil.
AU7087891A (en) Modified hil-6
DE69624657T2 (de) Verbesserung bei der Herstellung von N-[3-(3-Cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide
ATE263781T1 (de) Neurotrophischer al-1 faktor, einer ligand verwant mit dem eph tyrosine kinase receptor
DE69830143D1 (en) Phosphodiesterase 8
WO1999042596A3 (fr) Phosphodiesterase 10
ZA9710288B (en) Novel genes encoding telomerase proteins.
DE69333954D1 (de) An der streptogramin biosynthese beteiligte polypeptide, ihre kodierenden nukleotidsequenzen und ihre verwendung
EP0293646A3 (en) Subassembly consisting of several independently actuable multiple-way valves
GB2207982B (en) Valve base with integral flow controls
DE3750565D1 (de) Lungenautomat mit Vorsteuerventil.
EP0363436A4 (fr) Genes clones de variantes de la proteine g et variantes de la proteine g exprimees par ces genes.
AU7436087A (en) Distribution valve with precision flow control
WO1995000554A3 (fr) Recepteurs de cellules souches hematopoietiques totipotentes et leurs ligands
DE68910868D1 (de) Behälter für Flüssiggas-Brennstoff mit nichtverstellbarem Ventil.
EP0418579A3 (en) Internal tank valve
DE59003320D1 (de) Ventilkörperpaarung.
FI842013A (fi) Regleranordning foer valspress.
Weinberg What is protocorinthian geometric ware?
GB2201754B (en) Flow control valve.

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase